Assessment Status
Closed
The 2015 ICER Policy Summit convened an influential group of evidence policy leaders from insurers, pharmacy benefit management firms, and life science companies to discuss indication-specific pricing (ISP) of biopharmaceuticals and to explore the opportunities and challenges of ISP in the US health care system.
Date of review: December 2015
For more information, please contact info@icer.org.
Below you will find the final documents from the policy paper review process:
Held from December 9-11, 2015 the Policy Summit brought together 44 health care leaders from 22 payer and life sciences organizations. ICER staff developed a background paper on ISP prior to the meeting to provide participants with a common foundation in some of the key conceptual and practical issues. To create an environment of frank, open discussion the Summit was held under the “Chatham House Rule” whereby participants are able to share comments and perspectives heard at the meeting, but commit to not identifying the person or organization making the statement.
Public Comments
Closed